TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02826473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BRAINCHECK
Description: Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
Study: NCT04569344

Intervention type: OTHER
Intervention: Laboratory test positive for SARS-CoV-2 virus
Description: Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
Study: NCT01908244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Pentatonic music
Study: NCT02194075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine+Methylphenidate hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvoxamine+sugar pill
Study: NCT02879162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study: NCT02293499

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLASMA
Description: A structured asthma self-management manual (Let's Talk about Asthma \[LTAA\],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLASMA
Description: A structured asthma self-management manual (Let's Talk about Asthma \[LTAA\],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site.
Study: NCT04924491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous thyTreg
Description: Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous thyTreg
Description: Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
Study: NCT02361931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A hydrogel containing erythropoietin
Description: Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogel (as a part of SOC)
Description: Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
Study: NCT02329288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03527602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement
Description: After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
Study: NCT05051839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surgery and restoration
Description: Implants with two different transmucosal neck configuration are placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surgery and restoration
Description: Implants with two different transmucosal neck configuration are placed.
Study: NCT03117127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Eggs
Description: Participants will ingestion whole eggs immediately after resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Whites
Description: Participants will ingestion whole eggs immediately after resistance exercise
Study: NCT02214082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same Day Discharge
Description: This group will be discharged home, on the same day after their elective angioplasty
Study: NCT01237730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime
Description: Use the cefuroxime as prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored antibiotic
Description: Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
Study: NCT03168724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT intervention
Study: NCT04136132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
Study: NCT03588520

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring
Description: Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
Study: NCT03877809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 0.5 mg
Description: Daily administration of 1 or more tablets
Study: NCT01141309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib with everolimus
Description: Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles \*Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study.
Study: NCT01958684

Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: LNG-IUS once inserted will be effective for 5 years.

Intervention type: DEVICE
Intervention: Copper-IUD
Description: Copper-IUD once inserted will be effective for more than 10 years.
Study: NCT02090595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-C
Description: A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
Study: NCT01233830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution
Study: NCT03096353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
Study: NCT02748993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 Cream 0.1%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 Cream 0.3%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 Cream 1.0%
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 Cream Vehicle
Description: Topical application
Study: NCT03617432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT00618150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: An educational program: Three lessons spaced over 2 weeks.
Study: NCT01802359

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
Study: NCT04290182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-KI-PL-204
Description: Autologous MSC product
Study: NCT00701987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-357
Description: Topical application of ALS-357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-357
Description: Topical application of ALS-357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-357
Description: Topical application of ALS-357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-357
Description: Topical application of ALS-357
Study: NCT02133417

Intervention type: DEVICE
Intervention: Quantitative Transmission Ultrasound
Description: Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
Study: NCT01964248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream applied 2 hours before blood sample

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaïne/prilocaïne 5%
Description: Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
Study: NCT02547623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: depot intracameral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone eye drops 1%
Study: NCT03728049

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-ADP performed during TAVI procedure
Description: The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: No CT-ADP performed during TAVI procedure
Description: PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
Study: NCT05196893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link Intervention
Description: Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link Intervention
Description: Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
Study: NCT01795651

Intervention type: PROCEDURE
Intervention: identification of take-home message of lecture
Study: NCT00826514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Intravenous, 20 mg, single dose.
Study: NCT03617432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT00826514

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo, single dose
Study: NCT03617432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT01219621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symphony Dual Chamber Rate Responsive Device
Description: Echocardiography ANP/BNP measurements
Study: NCT00984945

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5 VLP pandemic influenza vaccine 5 µg
Description: 0.5 mL, IM, 2 injections 21 days apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5 VLP pandemic influenza vaccine 10 µg
Description: 0.5 mL, IM, 2 injections 21 days apart
Study: NCT03678974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
Study: NCT00749606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual telephone intervention
Description: Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group telephone intervention
Description: Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff.
Study: NCT01219621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symphony Dual Chamber Rate Responsive Device
Description: Echocardiography ANP/BNP measurements
Study: NCT00984945

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5 VLP pandemic influenza vaccine 20 µg
Description: 0.5 mL, IM, two injections 21 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL, IM, two injections 21 days apart
Study: NCT04148729

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
Study: NCT03808103

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, twice a day, for a period of fifteen days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage preparation
Description: Orally, twice a day, for a period of fifteen days
Study: NCT04247048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infusion of tracer [5,5,5-2H3] -L-leucine
Description: A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infusion of tracer [5,5,5-2H3] -L-leucine
Description: A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
Study: NCT03681717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study: NCT01577862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: 2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: 2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg every 12 hours intravenously